CAMBRIDGE, Mass.–(BUSINESS WIRE)–Brixton Biosciences (Brixton), a clinical-stage life sciences company focused on developing a nerve-selective biomaterial designed to provide targeted and durable relief from pain, today announced the appointments of David Acheson as Chief Commercial Officer and Brian Newkirk as Chief Business Officer. The appointments strengthen Brixton’s executive leadership team as the Company prepares for potential commercialization of its lead product, Reneurx™ Nerve-Sele